Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus chemotherapy for perioperative treatment of initially unresectable NSCLC
ChiCTR2400083838Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Surgical conversion rate. Planned start May 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400083838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083838.